2|0|Public
50|$|<b>Nelivaptan</b> (SSR149415) and D-Leu4-Lys8-vasopressin are a {{specific}} antagonist and agonist for the vasopressin 1b receptor, respectively.|$|E
5000|$|<b>Nelivaptan</b> (INN) (developmental codename SSR-149,415) is a selective, orally active, non-peptide {{vasopressin}} receptor antagonist selective for the V1B subtype. [...] The drug {{had entered}} clinical trials {{for treatment of}} anxiety and depression. In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.|$|E

